Efficacy of local infiltration analgesia with ropivacaine for postoperative pain management in cervical laminoplasty: a retrospective study

Kunpeng Li, Hao Li, Dawei Luo, Hongyong Feng, Changbin Ji, Keshi Yang, Jinlong Liu, Honglei Zhang & Hui Xu*

Poor postoperative pain control impairs patient recovery and lengthens the duration of hospitalization after various surgeries. Local infiltration analgesia (LIA) has become an effective method for managing postoperative pain. This study aimed to investigate the efficacy of LIA with ropivacaine for postoperative pain control after cervical laminoplasty. In total, 68 patients undergoing cervical laminoplasty were included for retrospective review and divided into ropivacaine and control groups. The visual analogue scale (VAS) score, postoperative analgesic consumption, operative duration, intraoperative blood loss volume, incision length, hospitalization duration and incidence of complications were analyzed. In the ropivacaine group, the VAS score was 3.2 ± 1.4 at 4 hours postoperatively, which was lower than that of the control group (4.0 ± 1.4, P = 0.024). At 8, 12 and 24 hours after surgery, a significant difference was detected in the VAS score between the two groups (P ≤ 0.015). Sufentanil consumption was less in the ropivacaine group than in the control group in the first 4 hours postoperatively (25.6 ± 6.3 µg vs 32.2 ± 6.8 µg, P < 0.001), and similar results were observed in the first 8, 12, 24, 48 and 72 hours postoperatively (P < 0.001). Fewer patients required rescue analgesia in the ropivacaine group (8/33 vs 18/35 at 4–8 hours, P = 0.021; 9/33 vs 21/35 at 8–12 hours, P = 0.007). The hospitalization duration and time to ambulation were shorter in the ropivacaine group (8.5 ± 1.4 vs 9.6 ± 1.6 for postoperative duration, P = 0.002; 2.9 ± 0.7 vs 3.5 ± 0.8 for time to ambulation, P = 0.001). The incidence of nausea and vomiting was lower in the ropivacaine group than in the control group (30.3% vs 54.3%, P = 0.046). In conclusion, LIA with ropivacaine could effectively reduce postoperative pain, and postoperative analgesic consumption, and promote recovery after cervical laminoplasty.

Cervical laminoplasty has been used widely and achieved satisfactory outcomes in treating multilevel cervical lesions, including cervical spondylotic myelopathy (CSM), congenital cervical stenosis (CCS), and ossification of the posterior longitudinal ligament (OPLL)1–3. However, surgical treatment often results in serious pain, which can impair patient recovery and lengthen the hospitalization duration. Recently, local infiltration analgesia (LIA) has emerged as a good choice for postoperative analgesia due to its simplicity and low-cost4–6. LIA has been used in various surgeries with favorable outcomes and without major side effects6. The benefits of LIA in spinal surgery are also well known; however, its use has been limited to lumbar decompression and discectomy, and spinal fusion surgery7,8. Few studies have focused on the effect of LIA on postoperative pain control in cervical laminoplasty.

Therefore, we conducted this clinical study to retrospectively evaluate the efficacy of LIA with ropivacaine for managing postoperative pain after cervical laminoplasty.
Methods and Materials

Patient population. This was a retrospective study conducted in the Department of Spinal Surgery, Liaocheng People's Hospital, between January 2014 and December 2016. The inclusion criteria were as follows: age 18–75 years; primary diagnosis of CSM, CCS, or OPLL, involvement of 3 or more segments; and treatment with expansive open-door cervical laminoplasty. The exclusion criteria were American Society of Anesthesiologists physical status III or higher, history of cervical surgery, and the presence of myelopathy caused by trauma, tumors or infections.

All patients who underwent posterior cervical laminoplasty from January 2014 to December 2016 were reviewed. Only 68 patients who met the inclusion criteria and provided written informed consent were included in this trial. The enrolled patients were divided into two groups: 33 patients which received LIA with ropivacaine comprised the ropivacaine group, and 35 patients who did not receive LIA comprised the control group. The study was approved by the Ethics Committee of Liaocheng People's Hospital, and written informed consent was provided by every patient before enrollment. All procedures in this study were performed according to the relevant guidelines and regulations.

Previous literature has reported that a difference of 1.0 to 1.3 points on the visual analogue scale (VAS) is clinically important. Elder showed a standard deviation of 1.97 on the VAS following cervical laminoplasty. Additionally, we reviewed several similar reports and found that the number of the treated subjects was approximately 30. Therefore, we determined that a total of 30 patients per group was required to detect a 1.5-point difference on the VAS (power = 80%, p = 0.05). The power was 0.815 according to data mentioned above (n = 30, σ = 2.0, k = 1.5, α = 0.05). The sample size and power analysis were performed using the Power and Sample Size Program (Power and Sample Size Calculation version 3.1.6, Copyright © 1997–2009 by William D. Dupont and Walton D. Plummer, Jr).

Surgical procedure. The surgical procedure was performed as described in a previous report by Li. All patients received general anesthesia with 0.1% propofol, dexmedetomidine, fentanyl, remifentanil, and cisatracurium. The patients were positioned in prone with slight flexion of the neck in a Mayfield head fixator. A standard posterior midline incision was performed and the lamina were exposed to medial facet joints from C3 to C7. A hinge was made on the side with fewer symptoms by removing the dorsal cortex and cancellous bone, while the lamina along the medial margin of the facet joints was completely removed on the open side. After elevating the opening lamina approximately 1 cm, a titanium plate was placed on each segment. Two screws were implanted to fix the plate tightly to the lamina and lateral mass. Electrocardiography, blood pressure, pulse oximetry, and arterial blood gas were routinely monitored.

No preemptively scheduled analgesic regimen was employed.

LIA. Before the incision line was closed after decompression and fixation, 10 ml of ropivacaine (concentration: 0.75%) was administered over the incision line into paravertebral muscles, and the subcutaneous, and cutaneous tissue along the wound edge. After surgery, the patient was placed in the supine position, and was extubated successfully on the table. Once the patient was awake and responding to verbal commands, he or she was transferred to the postanesthesia care unit, and then to the spine ward for further monitoring and recovery care.

Postoperative management. Every patient received patient-controlled analgesia (PCA) with 0.8 μg/ml sufentanil for 72 hours postoperatively. The PCA pump was set so that one pump press delivered a 2-ml bolus with no continuous background infusion. The sufentanil was given at a bolus of 2 ml (1.6 μg) with a 5-minute lockout time, and the maximum dosage was 12.8 μg per hour. When a patient indicated a VAS score ≥5, flurbiprofen axetil was given as a rescue analgesic.

Prophylactic antibiotics were administered for 24 hours after surgery. All patients were encouraged to start out-of-bed activity with a cervical brace within one week after surgery. Mechanical thrombophrophylaxis was given to every patient to prevent phlebothrombosis in both legs. Clinical and radiological assessments were performed in the orthopedic outpatient clinic every three months after discharge from the hospital.

Observed indexes. The postoperative VAS score and sufentanil consumption were recorded at 4, 8, 12, 24, 48 and 72 hours after surgery to evaluate pain severity. The number of patients who required rescue analgesia (flurbiprofen axetil) was also recorded postoperatively. The operative duration, intraoperative blood loss volume and incision length were quantified to evaluate the surgical trauma. The recovery time including the length of total and postoperative hospital duration and the time to ambulation was recorded.

The incidence of complications, including postoperative nausea and vomiting (PONV) and wound infection, was also analyzed in this study.

Statistical analyses. Data analyses were performed with the SPSS 17.0 statistical package (SPSS, Chicago, U.S.A.). In this study, continuous data, including VAS, sufentanil consumption, operative indexes and recovery time, are presented as the mean±standard deviation and were analyzed with the two-sample t-test and ANOVA. The chi-squared test was used to analyze categorical data, such as the number of patients requiring rescue analgesia and the incidence of complications. All reported p values were from 2-sided tests. A P value lower than 0.05 was regarded as statistically significant.
Results

In this study, 68 patients undergoing posterior expansive open-door cervical laminoplasty were included, with 33 in the ropivacaine group and 35 in the control group. The patients’ demographics information and basic characteristics, including age, sex, weight, height, BMI and fracture level are shown in Table 1 and there were no significant differences between the two groups.

Operative indexes.

The operative duration was slightly longer in the ropivacaine group (121 ± 24 min) than in the control group (117 ± 19 min), but no significant difference was observed (P = 0.46). Similar results were observed between the two groups for the intraoperative blood loss volume and incision length (295.2 ± 75.1 ml vs 310.6 ± 80.2 ml, P = 0.42; 14.6 ± 1.2 cm vs 14.2 ± 1.1 cm, P = 0.25, ropivacaine vs control group, respectively) (Table 2).

Recovery time.

The average total hospitalization duration was significantly shorter in the ropivacaine group (10.6 ± 1.5 days) than in the control group (11.7 ± 1.6 days, P = 0.006). Significant differences were found in the postoperative hospitalization and the time to ambulation between the ropivacaine and control groups (P = 0.002 and P = 0.001, respectively) (Table 3).

Evaluation of pain severity.

The average VAS score 4 hours postoperatively was lower in the ropivacaine group (3.2 ± 1.4 points) than in the control group (4.0 ± 1.4 points, P = 0.024). At 8, 12 and 24 hours after surgery, there was a significant difference in the VAS score between the two groups (P ≤ 0.015). However, no significant difference was found at 48 hours and 72 hours postoperatively (P = 0.42 and P = 0.66, respectively) (Fig. 1). The change in VAS scores over time in the first 72 hours postoperatively was shown in Fig. 2.

Analgesic consumption.

The sufentanil consumption in the ropivacaine group was less than the control group in the first 4 hours postoperatively (25.6 ± 6.3 µg vs 32.2 ± 6.8 µg, P < 0.001). Similar results were found regarding the cumulative sufentanil consumption in the first 8, 12, 24, 48 and 72 hours after surgery (P < 0.001) (Fig. 3).

Parameter | Ropivacaine group | Control group | P value
---|---|---|---
Number of patients | 33 | 35 | 
Age (year) | 60.0 ± 6.6 (49-70) | 59.2 ± 7.4 (47-75) | 0.62
Sex, male/female | 25/10 | 22/11 | 0.68
Weight (kg) | 68.2 ± 8.0 | 67.2 ± 7.8 | 0.60
Height (cm) | 169 ± 6.9 | 169.7 ± 6.9 | 0.67
BMI (kg/m²) | 23.8 ± 1.8 | 23.3 ± 1.9 | 0.23
Diagnosis | | | 0.79
CSM | 11 | 13 | 
OPLL | 8 | 10 | 
CSS | 14 | 12 | 
Study Parameters | Ropivacaine group | Control group | P value
---|---|---|---
Operative duration (min) | 121 ± 24 | 117 ± 19 | 0.46
Intraoperative blood loss volume (ml) | 295.2 ± 75.1 | 310.6 ± 80.2 | 0.42
Incision length (cm) | 14.6 ± 1.2 | 14.2 ± 1.1 | 0.25

Table 1. Characteristics of the patients in both groups. CCS = cervical canal stenosis, CSM = cervical spondylotic myelopathy, OPLL = ossification of the posterior longitudinal ligament.

Table 2. Operative indexes for both groups.

Table 3. Recovery time for the patients in both groups.
In the ropivacaine group, the sufentanil consumption was 31.8 ± 6.9 µg from 4–8 hours postoperatively, which was less than that in the control group (40.1 ± 5.7 µg, P < 0.001). Similar results were found from 8–12 hours and 12–24 hours postoperatively (P < 0.001 and P = 0.023). However, no significant difference was observed from 24–48 hours, or 48–72 hours between the two groups (P = 0.36 and P = 0.63) (Fig. 4). The change in sufentanil consumption over time in the first 72 hours postoperatively was shown in Fig. 5.

Five patients in the ropivacaine group and 9 in the control group required the administration of flurbiprofen axetil in the first 4 hours after surgery, with no significant difference between the groups (P = 0.28). However, there was a significant difference in the number of patients requiring flurbiprofen axetil in the 4–8 hours and 8–12 hours after surgery (8/33 vs 18/35, P = 0.021; 9/33 vs 21/35, P = 0.007) (Table 4).

**Complications.** No case of clinical deterioration, permanent morbidity or mortality occurred in this study. In terms of the incidence of PONV, a significant difference was observed between the two groups (30.3% vs 54.3%, ropivacaine vs control group, P = 0.046). There was one case of wound infection in each group, and in both cases, the patient recovered after routine antibiotic treatment and dressing changes (Table 5).

**Discussion**

In the current study, we adopted LIA with 0.75% ropivacaine in posterior cervical laminoplasty to assess its efficacy in postoperative pain management. The results show significantly better outcomes for most parameters in the ropivacaine group than in the control group. LIA with ropivacaine could reduce pain severity and the consumption of opioid drugs via PCA after surgery and decrease the number of patients who required rescue analgesia. The data further indicated a lower incidence of PONV and a shorter hospitalization duration in the ropivacaine group.

LIA has been used in many surgeries as a pain control technique, and a series of reports has documented the use of this technique and its satisfactory outcomes in orthopedic, gynecological and abdominal surgeries. Sun and
Figure 3. Line graph showing the cumulative sufentanil consumption over the first 72 h postoperatively for the ropivacaine and control groups. Statistical significance was found at each time point over the first 72 h after surgery; h = hours postoperatively.

Figure 4. Boxplot showing sufentanil consumption at 0–4 h, 4–8 h, 8–12 h, 12–24 h, 24–48 h and 48–72 h postoperatively for the ropivacaine and control groups. The boxes indicate the interquartile range, the crosses within the boxes indicate the median, and the whiskers indicate the range. The asterisks indicate significance (P < 0.05); h = hours postoperatively.

Figure 5. Line graph showing the change in sufentanil consumption over time. The mean sufentanil consumption and error bar are plotted for each period for the patients in the ropivacaine group and the control group. h = hours postoperatively.
Within 72 hours was also less in the LIA patients than in the control patients. These findings are similar to those reported that the postoperative hospital stay was a better indicator of patient recovery. The use of LIA with ropivacaine could provide pain relief over the first 24 hours after surgery. This difference may be attributed to the longer duration of ropivacaine administration during the LIA procedure compared with that of bupivacaine. Previous studies have confirmed that as a propyl analog of bupivacaine, ropivacaine has a longer duration of action and is much safer than bupivacaine in terms of the cardiotoxicity profile.

In the current study, we recorded several operative indexes including the operative duration, intraoperative blood loss volume, and incision length, to assess the surgical trauma caused by posterior cervical laminoplasty. These indexes were similar in both groups and no significant differences were detected, which suggests that the surgical trauma to the patients was comparable. This finding indicates that the surgery caused postoperative pain of a similar severity in the two groups.

Effective pain management is now recognized as one of the three fundamental aspects of enhanced recovery after surgery. As a potentially effective fast-track method, the role of postoperative pain control has not been well established in posterior cervical laminoplasty. Therefore, we investigated the role of LIA with ropivacaine in the recovery of patients undergoing treatment with cervical laminoplasty. In our study, the results demonstrate that the total hospitalization duration of the ropivacaine group was shorter than that of the control group. Rao reported that the postoperative hospital stay was a better indicator of patient recovery. The use of LIA with ropivacaine could also shorten the postoperative hospitalization duration, which suggests that the use of LIA with ropivacaine could effectively enhance the recovery of patients after cervical laminoplasty. Another indicator that could reflect patient recovery is the time to ambulation. The time to ambulation in the ropivacaine group was shorter than that in the control group, indicating that the wound infiltration with ropivacaine could decrease postoperative pain and promote the earlier initiation of out-of-bed activity. Thus, the use of LIA with ropivacaine for anesthesia could be effective in promoting patient recovery after surgery. These results are consistent with other previous reports.

PONV is a very common complication following opioid-based intravenous PCA. PONV can cause dehydration, electrolyte imbalance, postoperative bleeding, wound dehiscence, and pulmonary aspiration, and further aggravate patient discomfort. In a randomized controlled trial, Li found that wound ropivacaine infiltration could decrease the incidence of PONV in patients receiving intravenous morphine for analgesia after lumbar fusion surgery. These results were confirmed by our research. Fewer patients who received the LIA with ropivacaine experienced PONV than patients in the control group, which may be due to the less consumption of sufentanil by those who received LIA with ropivacaine.

### Table 4. Administration of flurbiprofen axetil in both groups.

| Period       | Ropivacaine group | Control group | P value |
|--------------|-------------------|---------------|---------|
| First 4 hours| 5/33              | 9/35          | 0.28    |
| 4–8 hours    | 8/33              | 18/35         | 0.021   |
| 8–12 hours   | 9/33              | 21/35         | 0.007   |

### Table 5. Incidence of complications in both groups.

| Complication       | Ropivacaine group | Control group | P value |
|--------------------|-------------------|---------------|---------|
| PONV               | 10/33             | 19/35         | 0.046   |
| Wound infection    | 1/33              | 1/35          | >0.99   |
There are some limitations to this study that impair the ability to evaluate the effect of LIA with ropivacaine on postoperative pain management. First, this trial was retrospective, not randomized and not blinded, and was performed at a single center. Second, this study included a small number of patients. Prospective, randomized controlled studies, enrolling more patients and spanning multiple centers, are needed to further evaluate the efficacy of ropivacaine for managing postoperative pain after cervical laminoplasty.

Conclusion
In conclusion, LIA with ropivacaine could effectively reduce postoperative pain severity and postoperative analgesic consumption after cervical laminoplasty. Moreover, it could promote recovery after surgery.

Received: 19 October 2018; Accepted: 19 February 2020;
Published online: 06 March 2020

References
1. Fehlings, M. G. & Arvin, B. Surgical management of cervical degenerative disease: the evidence related to indications, impact, and outcome. Journal of neurosurgery. Spine 11, 97–100 (2009).
2. Chang, V. & Holly, L. T. Controversies in the management of cervical spondylotic myelopathy. Journal of neurosurgical sciences 57, 241–252 (2013).
3. Chen, H. et al. Clinical and radiography results of mini-plate fixation compared to suture suspensory fixation in cervical laminoplasty: A five-year follow-up study. Clinical neurology and neurosurgery 138, 188–195 (2015).
4. Swennen, C. et al. Local infiltration analgesia with ropivacaine in acute fracture of thoracolumbar junction surgery. Orthopaedics & traumatology, surgery & research: OTSR 103, 291–294 (2017).
5. Affas, F. Local infiltration analgesia in knee and hip arthroplasty efficacy and safety. Scandinavian journal of pain 13, 59–66 (2016).
6. Rothen, N. B. Wound infiltration for surgery. Anesthesia 65(Suppl 1), 67–75 (2010).
7. Gurbet, A. et al. Pre-emptive infiltration of levobupivacaine is superior to at-closure administration in lumbar laminectomy patients. European spine journal: official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 17, 1237–1241 (2008).
8. Elder, J. B., Hoh, D. J. & Wang, M. Y. Postoperative continuous paravertebral anesthetic infusion for pain control in lumbar spinal fusion surgery. Spine 33, 210–218 (2008).
9. Ashraf, A., Raut, V. V., Canty, S. J. & McLauchlan, G. J. Pain control after primary total knee replacement. A prospective randomised controlled study of local infiltration analgesia with ropivacaine. The Knee 20, 324–327 (2013).
10. Elder, J. B., Hoh, D. J., Liu, C. Y. & Wang, M. Y. Postoperative continuous paravertebral anesthetic infusion for pain control in posterior cervical spine surgery: a case-control study. Neurosurgery 66, 99–106; discussion 106–107 (2010).
11. Rao, Z. et al. Ropivacaine wound infiltration: a fast-track approach in patients undergoing thoracotomy surgery. The Journal of surgical research 220, 379–384 (2017).
12. Kuchalka, J., Magnuson, A., Lundin, A. & Gupta, A. Local infiltration analgesia or femoral nerve block for postoperative pain management in patients undergoing total hip arthroplasty. A randomized, double-blind study. Scandinavian journal of pain 16, 223–230 (2017).
13. Li, K. et al. Safety and efficacy of cervical laminoplasty using a piezosurgery device compared with a high-speed drill. Medicine 95, e4913 (2016).
14. Sun, J. X. et al. Effect of local wound infiltration with ropivacaine on postoperative pain relief and stress response reduction after open hepatectomy. World journal of gastroenterology 23, 6733–6740 (2017).
15. O’Neill, P. R., Duarte, F., Ribeiro, I., Centeno, M. J. & Moreira, J. Ropivacaine continuous wound infusion versus epidural morphine for postoperative analgesia after cesarean delivery: a randomized controlled trial. Anesthesia and analgesia 114, 179–185 (2012).
16. Koehler, D., Marsh, J. L., Karam, M., Fruehling, C. & Willey, M. Efficacy of Surgical-Site, Multimodal Drug Injection Following Operative Management of Femoral Fractures: A Randomized Controlled Trial. The Journal of bone and joint surgery. American volume 99, 512–519 (2017).
17. Meng, X. et al. A comparison of the postoperative analgesic efficacy between epidural and intravenous analgesia in major spine surgery: a meta-analysis. J. Pain Res. 10, 405–415 (2017).
18. Singh, K. et al. Multimodal Analgesia Versus Intravenous Patient-Controlled Analgesia for Minimally Invasive Transforaminal Lumbar Interbody Fusion Procedures. Spine 42, 1145–1150 (2017).
19. Mulliken, J. B. & Cook, W. A. Jr. Reduction of postoperative lumbar hemilaminectomy pain with Marcaine. Technical note. Journal of neurosurgery 51, 126–127 (1979).
20. Andersen, K. V., Pfeiffer-Jensen, M., Haraldsted, V. & Soballe, K. Reduced hospital stay and narcotic consumption, and improved mobilization with local and intrathoracical infiltration after hip arthroplasty: a randomized clinical trial of an intrathoracical technique versus epidural infusion in 80 patients. Acta orthopaedica 78, 180–186 (2007).
21. Gottschalk, A. et al. Continuous wound infiltration with ropivacaine reduces pain and analgesic requirement after shoulder surgery. Anesthesia and analgesia 97, 1086–1091, table of contents (2003).
22. Mitra, S., Purohit, S. & Sharma, M. Postoperative Analgesia After Wound Infiltration With Tramadol and Dextrometomidine as an Adjuvant to Ropivacaine for Lumbar Discectomies: A Randomized-controlled Clinical Trial. Journal of neurosurgical anaesthesiology 29, 433–438 (2017).
23. Kuthiala, G. & Chaudhary, G. Ropivacaine: A review of its pharmacology and clinical use. Indian journal of anaesthesia 55, 104–110 (2011).
24. Nimo, S. M., Foo, I. T. H. & Paterson, H. M. Enhanced recovery after surgery: Pain management. Journal of surgical oncology 116, 583–591 (2017).
25. Gupta, T., Garg, N. & Gupta, M. Local infiltration analgesia following total hip replacement: a review of current literature. Chinese journal of traumatology = Zhonghua chuang shang za zhi 17, 293–297 (2014).
26. Cao, X., White, P. F. & Ma, H. An update on the management of postoperative nausea and vomiting. Journal of anesthesia 31, 617–626 (2017).
27. Li, J., Yang, J. S., Dong, B. H. & Ye, J. M. The Effect of Dexametomidine Added to Preemptive Ropivacaine Infiltration on Postoperative Pain after Lumbar Fusion Surgery: A Randomized Controlled Trial. Spine (2019).

Acknowledgements
This research was financially supported by the Natural Science Foundation of Shandong (Grant Nos: ZR2017MH112 and ZR2014HL027).
Author contributions
X.H. and L.K.P. conceived and designed the study. L.K.P., L.H., F.H.Y. and X.H. wrote and revised the main manuscript. J.C.B., L.D.W. and Y.K.S. collected and analyzed the data. L.D.W., L.J.L. and Z.H.L. prepared all the figures. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to H.X.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020